Nicht-tuberkulöse Mykobakteriosen bei der HIV-Infektion

Zusammenfassung

Infektionen mit nicht-tuberkulösen Mykobakterien (NTM) gehören zu den AIDS-definierenden Erkrankungen der HIV-Infektion. Immunsupprimierte Patienten mit weniger als 50 CD4+ T-Lymphozyten/µl im peripheren Blut sind besonders gefährdet, daran zu erkranken. Über 90 % der NTM-Infektionen bei HIV-seropositiven Patienten werden durch Bakterien des M.-avium-Komplex verursacht. Die Krankheitsbilder der NTM-Infektionen sind in der Regel nicht erregerspezifisch. Für die klinisch oft schwierige Abgrenzung einer Infektion von einer Kolonisation, z. B. beim Nachweis von NTM-Spezies aus bronchopulmonalen Sekreten, sind die Kriterien der American Thoracic Society und der Infectious Diseases Society of America (ATS/IDSA) hilfreich. Die Behandlung von Infektionen mit NTM erfolgt in Abhängigkeit von der Spezies mit einer Kombinationstherapie aus 2 – 4 Medikamenten. Im Gegensatz zur Therapie der Tuberkulose sind die Ergebnisse der in vitro Resistenztestungen von antimykobakteriellen Antibiotika bei NTM oft nicht aussagekräftig. Wechselwirkungen mit antiretroviralen Medikamenten werden häufig beobachtet. Diese komplexen Zusammenhänge werden aus epidemiologischer, mikrobiologischer und klinischer Perspektive erörtert

Abstract

Infections with non-tuberculous mycobacteria (NTM) belong to the AIDS-defining illnesses of HIV infection. Severe immunosuppression with CD4+ lymphocyte counts lower than 50 cells/µl is a risk factor for the acquaintance of NTM infections. More than 90 % of NTM infections in HIV-seropositive individuals are caused by bacteria of the M. avium complex. The manifestations of the disease are heterogeneous and not specific for the causative mycobacterial species. Furthermore, the differentiation between infection and colonisation can be challenging, especially when NTM are isolated from respiratory specimen. Diagnosis and therapy are recommended according to the guidelines of the American Thoracic Society and the Infectious Diseases Society of America (ATS/IDSA). The treatment success relies on the effects of antiretroviral therapy and a combination of 2 – 4 antimycobacterial antibiotics tailored to the NTM species. In vitro resistance testing often does not predict the clinical response. Interactions with antiretroviral medications are common. The complexity of HIV/NTM co-infection is discussed from an epidemiological, microbiological and clinical perspective.

AIDS - HIV-Infektion - Immunrekonstitutionssyndrom (IRIS) - nichttuberkulöse Mykobakterien - Mycobacterium-avium-Komplex

AIDS - HIV infection - immune reconstitution inflammatory syndrome (IRIS) - non-tuberculous mycobacteria (NTM) - Mycobacterium avium complex

Literatur

• 1 Mocroft A, Sterne J. Antiretroviral Therapy Cohort Collaboration (ART-CC) . Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.  Clin Infect Dis. 2009;  48 1138-1151
• 2 Benson C, Williams P, Currier J. et al . A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome.  Clin Infect Dis. 2003;  37 1234-1243
• 3 Chaisson R E, Keiser P, Pierce M. et al . Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic: Mycobacterium avium complex disease in patients with HIV infection.  AIDS. 1997;  11 311-317
• 4 Griffith D E, Aksamit T, Brown-Elliott B A. et al . An Official ATS/IDSA Statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.  Am J Respir Crit Care Med. 2007;  175 367-416
• 5 Jones D, Havlir D V. Nontuberculous mycobacteria in the HIV infected patient.  Clin Chest Med. 2002;  23 665-674
• 6 Jones J, Hanson D, Dworkin M. et al . Surveillance for AIDS-defining opportunistic illnesses, 1992 – 1997.  MMWR CDC Surveill Summ. 1999;  48 1-22
• 7 Karakousis P C, Moore R D, Chaisson R E. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy.  Lancet Infect Dis. 2004;  4 557-565
• 8 Lange C G, Woolley I J, Brodt R H. Disseminated Mycobacterium avium-intracellulare Complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?.  Drugs. 2004;  64 679-692
• 9 Lawn S, Bekker L, Miller R. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals.  Lancet Infect Dis. 2005;  5 361-373
• 10 Leung K L, Yip C W, Cheung W F. et al . Development of a simple and low-cost real-time PCR method for the identification of commonly encountered mycobacteria in a high throughput laboratory.  J Applied Microbiol. 2009;  107 1433-1439
• 11 Li H, Turhan V, Chokhani L. et al . Identification and differentiation of clinically relevant mycobacterium species directly from acid-fast bacillus-positive culture broth.  J Clin Microbiol. 2009;  47 3814-3820
• 12 Marras T K, Daley C L. A Systematic Review of the Clinical Significance of Pulmonary Mycobacterium kansasii Isolates in HIV Infection.  J Acquir Immune Defic Syndr. 2004;  36 883-889
• 13 Martín-Casabona N, Bahrmand A R, Bennedsen J. et al . Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey.  Int J Tuberculosis Lung Dis. 2004;  8 1186-1193
• 14 Mocroft A, Katlama C, Johnson A M. et al . AIDS across Europe, 1994 – 98: the EuroSIDA study.  Lancet. 2000;  356 291-296
• 15 Phillips P, Bonner S, Gataric N. et al . Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.  Clin Infect Dis. 2005;  41 1483-1497
• 16 Phillips P, Chan K, Hogg R. et al . Azithromycin prophylaxis for mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program.  Clin Infect Dis. 2002;  34 371-378
• 17 Rigsby M O, Curtis A M. Pulmonary disease from nontuberculous mycobacteria in patients with human immunodeficiency virus.  Chest. 1994;  106 913-919
• 18 Thomson R M, Yew W-W. When and how to treat pulmonary non-tuberculous mycobacterial diseases.  Respirology. 2009;  14 12-26
• 19 van Ingen J, Bendien S A, de Lange W CM. et al . Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands.  Thorax. 2009;  64 502-506